ABSTRACT
Hodgkin's disease-related deaths have decreased, overall mortality remains above that of the general population largely because of the development of congestive heart failure and secondary malignancy ("treatment toxicities") [2]. Secondary cancers developing after treatment for Hodgkin's disease are acute myelogenous leukemia (AML) 3.6%, non-Hodgkin's lymphomas 1.3%, and solid tumors 8.3% [3]. The risk increases with the more aggressive treatment regimens for primary Hodgkin's disease.
